SCHEMBL542379

SCHEMBL542379

Oc1ccc(C(F)(F)C(F)(F)[C](F)F)cc1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ESR1 P03372 10/20 0.50
ESR2 Q92731 10/20 0.50
KIF11 P52732 1/20 0.48
CYP3A4 P08684 3/20 0.42
LMNA P02545 2/20 0.42
TYR P14679 2/20 0.42
HPGD P15428 2/20 0.42
HSD17B10 Q99714 2/20 0.42
AR P10275 1/20 0.42
TSHR P16473 1/20 0.42
SLC6A2 P23975 1/20 0.42
SLC6A4 P31645 1/20 0.42
HTR6 P50406 1/20 0.42
ESRRG P62508 1/20 0.42
SLC6A3 Q01959 1/20 0.42
ALDH1A1 P00352 2/20 0.38
KDM4E B2RXH2 1/20 0.38
MEN1 O00255 1/20 0.38
NPC1 O15118 1/20 0.38
CA12 O43570 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2868121 0.82 ESR1 (0.62) ESR1ESR2KIF11CYP3A4LMNA
SCHEMBL9115517 0.78 ALDH1A1 (0.48) ESR1ESR2KIF11CYP3A4TSHR
SCHEMBL1026404 0.77 ESR1 (0.64) ESR1ESR2KIF11CYP3A4LMNA
SCHEMBL5013105 0.77 ESR1 (0.56) ESR1ESR2KIF11CYP3A4LMNA
SCHEMBL15084263 0.75 ESR1 (0.54) ESR1ESR2KIF11CYP3A4LMNA
SCHEMBL5068336 0.73 ESR1 (0.58) ESR1ESR2KIF11CYP3A4LMNA
SCHEMBL16626134 0.73 ESR1 (0.60) ESR1ESR2KIF11CYP3A4LMNA
SCHEMBL9508396 0.71 ESR1 (0.56) ESR1ESR2KIF11CYP3A4LMNA
SCHEMBL9400012 0.71 ESR1 (0.56) ESR1ESR2KIF11CYP3A4LMNA
SCHEMBL17943246 0.71 ACHE (0.62) ESR1ESR2KIF11CYP3A4LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8168666-B2 Substituted carbinol compound KOWA COMPANY, LTD. (JP) 2012-05-01 US disclosed
US-8153634-B2 Carbinol derivatives having cyclic linker KOWA COMPANY, LTD. (JP) 2012-04-10 US disclosed
EP-2098515-B1 SUBSTITUTED CARBINOL COMPOUND KOWA CO (JP) 2012-02-08 EP disclosed
EP-2281817-A1 SUBSTITUTED CARBINOL COMPOUND HAVING CYCLIC LINKER Kowa Company, Ltd. (JP) 2011-02-09 EP disclosed
US-20100063119-A1 SUBSTITUTED CARBINOL COMPOUND KOWA COMPANY, LTD. (JP) 2010-03-11 US disclosed
US-20100048610-A1 CARBINOL DERIVATIVES HAVING CYCLIC LINKER KOWA COMPANY, LTD. (JP) 2010-02-25 US disclosed
EP-2098515-A1 SUBSTITUTED CARBINOL COMPOUND Kowa Company. Ltd. (JP) 2009-09-09 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100063119-A1 SUBSTITUTED CARBINOL COMPOUND NR1H2, NR1H3, CYP46A1 ESR1 1176/4885ESR2 500/4885KIF11 4289/4885
US-20100048610-A1 CARBINOL DERIVATIVES HAVING CYCLIC LINKER NR1H2, NR1H3, LDLR ESR1 1307/4885ESR2 614/4885KIF11 4030/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.